# Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
Canonical URL: https://biopharmsignal.com/news/HUMA/humacyte-appoints-dr-todd-e-rasmussen-as-chief-surgical-officer
Ticker: HUMA
Company: Humacyte
Source: Humacyte
Published: 2026-05-12 12:00 EST
Original Source URL: https://investors.humacyte.com
## Summary

- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer - - Appointment brings important surgical experience and perspective to Humacyte’s corporate leadership team as clinical adoption of Symvess® ramps up

## Article Body
- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer - - Appointment brings important surgical experience and perspective to Humacyte’s corporate leadership team as clinical adoption of Symvess® ramps up
## Recent Company News
- 2026-05-26 12:00 EST — [Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access](https://biopharmsignal.com/news/HUMA/humacyte-announces-presentation-at-vasa-meeting-of-research-highlighting-self-repair-of-atev-after-cannulation-for-dialysis-access) — Source: Humacyte
- 2026-05-20 12:00 EST — [Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs](https://biopharmsignal.com/news/HUMA/humacyte-announces-symvessr-is-now-under-contract-with-the-strategic-acquisition-center-sac-of-the-u-s-department-of-veterans-affairs) — Source: Humacyte
- 2026-05-13 11:00 EST — [Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/HUMA/humacyte-announces-first-quarter-2026-financial-results-and-provides-business-update) — Source: Humacyte
- 2026-05-12 12:00 EST — [Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer](https://biopharmsignal.com/news/HUMA/humacyte-appoints-dr-todd-e-rasmussen-as-chief-surgical-officer) — Source: Humacyte
- 2026-05-08 12:00 EST — [Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026](https://biopharmsignal.com/news/HUMA/humacyte-to-announce-2026-first-quarter-financial-results-and-provide-business-update-on-may-13-2026) — Source: Humacyte
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)